At a glance
- Originator Aventis
- Class Antihyperlipidaemics; Benzamides
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 15 Feb 1995 Phase-II clinical trials for Hyperlipidaemia in USA (Unknown route)